Company News Summary
Acrux Announces Allowance of Underarm Administration Patent in US
Original announcement: Allowance of underarm administration patent in United States
Acrux confirmed that its patent application concerning the underarm administration of testosterone formulations has been allowed by the US Patent and Trademark Office (USPTO). The patent is expected to grant following payment of the issue fee. The USPTO's preliminary calculation of patent term adjustment is one additional year beyond the expiry date of June 2026. This will be re-calculated when the patent grants. A similar patent was previously granted in Australia, NZ, Singapore and South Africa and applications are under examination in a number of other countries around the world.
See more ASX300 News Announcements